These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 11146570)

  • 1. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
    Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of in vivo treatment with rh GM-CSF on in vitro growth of haematopoietic progenitors in patients with myelodysplastic syndromes.
    Visani G; Tosi P; Finelli C; Gamberi B; Zauli G; Cenacchi A; Fogli M; Colombini R; Tura S
    Haematologica; 1992; 77(2):142-5. PubMed ID: 1383105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro enhancement of erythropoiesis by steel factor in Diamond-Blackfan anemia and treatment of other congenital cytopenias with recombinant interleukin 3/granulocyte-macrophage colony stimulating factor.
    Sieff C; Guinan E
    Stem Cells; 1993 Jul; 11 Suppl 2():113-22. PubMed ID: 7691316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
    Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
    Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
    J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A; Shibata A
    Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
    Herrmann F; Mertelsmann R; Lindemann A; Ottmann OG; Seipelt G; Oster W; Hoelzer D; Ganser A
    Biotechnol Ther; 1991; 2(3-4):299-311. PubMed ID: 1845132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C
    Leuk Res; 2006 Apr; 30(4):385-8. PubMed ID: 16219350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.